Aclaris Therapeutics, Inc.
ACRS
$1.47
-$0.09-5.77%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -84.20% | 111.94% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -84.20% | 111.94% | |||
| Cost of Revenue | -28.52% | 119.12% | |||
| Gross Profit | -27.74% | -126.88% | |||
| SG&A Expenses | 23.92% | -12.37% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -17.36% | 66.09% | |||
| Operating Income | -26.40% | -45.49% | |||
| Income Before Tax | 84.38% | -1,172.77% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 84.38% | -1,172.77% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 84.38% | -1,172.77% | |||
| EBIT | -26.40% | -45.49% | |||
| EBITDA | -26.58% | -46.24% | |||
| EPS Basic | 87.83% | -853.06% | |||
| Normalized Basic EPS | -5.15% | -20.88% | |||
| EPS Diluted | 87.84% | -854.19% | |||
| Normalized Diluted EPS | -5.15% | -20.88% | |||
| Average Basic Shares Outstanding | 28.42% | 33.52% | |||
| Average Diluted Shares Outstanding | 28.42% | 33.52% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||